Orchard Therapeutics, a London, United Kingdom-based company developing gene therapies, completed a $150m Series C financing.
The round was led by Deerfield Management with new investments from RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management LP, ArrowMark Partners, Sphera Global Healthcare, Medison Ventures, Driehaus Capital Management and Ghost Tree Capital Group, LP, as well as additional U.S. based healthcare focused funds and existing investors Temasek, Baillie Gifford, RTW Investments, LP, Cowen Healthcare Investments and Agent Capital.
Led by Mark Rothera, president and CEO, Frank Thomas, CFO and chief business officer, Orchard Therapeutics is a commercial-stage biotechnology company developing innovative gene therapies.
The company’s portfolio of autologous ex vivo gene therapies includes Strimvelis, an autologous ex vivo gene therapy approved by the EMA for adenosine deaminase severe combined immunodeficiency (ADA-SCID). Additional programs for primary immune deficiencies, neurometabolic disorders and hemoglobinopathies include three advanced registrational studies for ADA-SCID, metachromatic leukodystrophy (MLD) and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD) and transfusion dependent beta-thalassemia (TDBT), as well as an extensive preclinical pipeline.
The company will use the proceeds to progress its three most advanced clinical programs:
– OTL-101 for adenosine deaminase severe combined immunodeficiency (ADA-SCID),
– OTL-200 for metachromatic leukodystrophy (MLD) and
– OTL-103 for Wiskott–Aldrich syndrome (WAS) towards registration and commercialization.
The funding will also support the clinical and preclinical development of the company’s rare disease gene therapy pipeline.
Orchard currently has offices in the U.K. and the U.S., including London, San Francisco and Boston.